Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Muik

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Science Immunology|September 20, 2022
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5Alexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Frontiers in Oncology|July 12, 2017
Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most EffectiveDina Kleinlützum, Julia D S Hanauer, Alexander Muik, et al.
Vaccine|August 28, 2024
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccineShanti Pather, Nicola Charpentier, Frank van den Ouweland, et al.
Cell Reports|August 4, 2024
Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1Alexander Muik, Jasmin Quandt, Bonny Gaby Lui, et al.
Emerging Microbes & Infections|July 6, 2022
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infectionChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
Computers in Biology and Medicine|February 12, 2023
Early computational detection of potential high-risk SARS-CoV-2 variantsKarim Beguir, Marcin J Skwark, Yunguan Fu, et al.
NPJ Vaccines|April 9, 2022
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variantsJianying Liu, Yang Liu, Hongjie Xia, et al.
Nature|June 10, 2021
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variantsJianying Liu, Yang Liu, Hongjie Xia, et al.
Cancer Research|May 10, 2014
Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potencyAlexander Muik, Lawton J Stubbert, Roza Z Jahedi, et al.
Clinical Pharmacology and Therapeutics|May 10, 2025
Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical DataGaurav Bajaj, Dmitry Shchelokov, Oleg Demin, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Science Immunology|September 20, 2022
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5Alexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Frontiers in Oncology|July 12, 2017
Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most EffectiveDina Kleinlützum, Julia D S Hanauer, Alexander Muik, et al.
Vaccine|August 28, 2024
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccineShanti Pather, Nicola Charpentier, Frank van den Ouweland, et al.
Cell Reports|August 4, 2024
Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1Alexander Muik, Jasmin Quandt, Bonny Gaby Lui, et al.
Emerging Microbes & Infections|July 6, 2022
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infectionChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
Computers in Biology and Medicine|February 12, 2023
Early computational detection of potential high-risk SARS-CoV-2 variantsKarim Beguir, Marcin J Skwark, Yunguan Fu, et al.
NPJ Vaccines|April 9, 2022
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variantsJianying Liu, Yang Liu, Hongjie Xia, et al.
Nature|June 10, 2021
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variantsJianying Liu, Yang Liu, Hongjie Xia, et al.
Cancer Research|May 10, 2014
Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potencyAlexander Muik, Lawton J Stubbert, Roza Z Jahedi, et al.
Clinical Pharmacology and Therapeutics|May 10, 2025
Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical DataGaurav Bajaj, Dmitry Shchelokov, Oleg Demin, et al.
Pageof 5